Baudax Bio, Inc., a pharmaceutical company specializing in hospital and acute-care products, has recently introduced their latest product, ANJESO (meloxicam), for the management of moderate to severe pain. With the option to take it alone or paired with other non-NSAID analgesics, this injection offers a versatile solution for medical professionals. Additionally, the company has several ongoing projects in developmental phases, including BX1000, a neuromuscular blocking agent in phase II clinical trial; BX2000, an ultra-short acting NMB in phase I clinical trial with a proprietary blockade reversal agent; and BX3000, a NMB reversal agent currently in preclinical studies. Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio is quickly making strides in the healthcare industry.
Baudax Bio, Inc.'s ticker is BXRX
The company's shares trade on the NASDAQ stock exchange
They are based in Malvern, Pennsylvania
There are 11-50 employees working at Baudax Bio, Inc.
It is https://www.baudaxbio.com/
Baudax Bio, Inc. is in the Healthcare sector
Baudax Bio, Inc. is in the Biotechnology industry
The following five companies are Baudax Bio, Inc.'s industry peers: